Mode of Death on Chagas Heart Disease: Comparison with Other Etiologies. A Subanalysis of the REMADHE Prospective Trial

Silvia M. Ayub-Ferreira*, Sandrigo Mangini, Victor S. Issa, Fátima D. Cruz, Fernando Bacal, Guilherme V. Guimarães, Paulo R. Chizzola, Germano E. Conceição-Souza, Fabiana G. Marcondes-Braga, Edimar A. Bocchi

Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Abstract

Background: Sudden death has been considered the main cause of death in patients with Chagas heart disease. Nevertheless, this information comes from a period before the introduction of drugs that changed the natural history of heart failure. We sought to study the mode of death of patients with heart failure caused by Chagas heart disease, comparing with non-Chagas cardiomyopathy.

Methods and results: We examined the REMADHE trial and grouped patients according to etiology (Chagas vs non-Chagas) and mode of death. The primary end-point was all-cause, heart failure and sudden death mortality; 342 patients were analyzed and 185 (54.1%) died. Death occurred in 56.4% Chagas patients and 53.7% non-Chagas patients. The cumulative incidence of all-cause mortality and heart failure mortality was significantly higher in Chagas patients compared to non-Chagas. There was no difference in the cumulative incidence of sudden death mortality between the two groups. In the Cox regression model, Chagas etiology (HR 2.76; CI 1.34–5.69; p = 0.006), LVEDD (left ventricular end diastolic diameter) (HR 1.07; CI 1.04–1.10; p < 0.001), creatinine clearance (HR 0.98; CI 0.97–0.99; p = 0.006) and use of amiodarone (HR 3.05; CI 1.47–6.34; p = 0.003) were independently associated with heart failure mortality. LVEDD (HR 1.04; CI 1.01–1.07; p = 0.005) and use of beta-blocker (HR 0.52; CI 0.34–0.94; p = 0.014) were independently associated with sudden death mortality.

Conclusions: In severe Chagas heart disease, progressive heart failure is the most important mode of death. These data challenge the current understanding of Chagas heart disease and may have implications in the selection of treatment choices, considering the mode of death.

Trial Registration: ClinicalTrials.gov NCT00505050 (REMADHE)

Introduction

Chagas disease (American trypanosomiasis) remains a burden for public health systems in Latin American countries [1]. In fact, the global prevalence of Chagas disease has reached 9 million people and 25 million are estimated to be at risk worldwide [2]. As a result of globalization and migration, non-endemic countries have reported an increase in the prevalence of Chagas disease. It has been estimated that 47,000 T. cruzi-infected persons are now living in Spain and another 300,000 in the United States [3].

Sudden death has been considered the main cause of death in patients with Chagas heart disease [4]. Nevertheless, this information comes mainly from a period before the introduction of drugs that changed the natural history of heart failure such as beta-blockers, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB). Furthermore, many studies that support this finding include heterogeneous cohorts of patients, in particular patients without ventricular dysfunction [4].

To the best of our knowledge there is not a recent publication studying the mode of death in Chagas heart disease. The management of Chagas heart disease is complex and includes the treatment of complex arrhythmias and heart failure. The precise understanding of current natural history of patients presenting systolic dysfunction is indispensable to plan adequate health politics and improve survival. Therefore, we sought to study the mode of death of patients with heart failure caused by Chagas heart disease, comparing with non-Chagas cardiomyopathy.

Materials and Methods

Patients

We examined the patients included in the REMADHE (Rеpetitive Еducation at Six-Month Intervals and Mоnitoring
Chagas disease remains a burden for public health systems in Latin American countries. Several authors believe that sudden death is the main cause of death in this population. So many efforts have been made to prevent sudden death in Chagas disease. In order to verify if sudden death is the leading cause of death in Chagasic heart failure, we performed a subanalysis of the REMADHE prospective trial, which included a population of outpatients in a tertiary referral center for heart failure. We grouped patients according to etiology (Chagas vs non-Chagas) and modes of death that were classified as progressive heart failure death, sudden death, other cardiovascular death, noncardiovascular death or unknown death. Our study showed that in this end of the spectrum of presentation of Chagas disease, with systolic heart dysfunction, progressive heart failure is the main mode of death. These data have implications for the development of new strategies for prevention of chagasic heart failure.

Definitions
Patients were divided into two groups: Chagas and non-Chagas. The diagnosis of Chagas disease was based on epidemiological information along with serological tests (indirect immunofluorescence, passive haemaglutination, immunoenzymatic assay) positive for *Trypanosoma cruzi* [7]. Patients with an alternative diagnosis, or a mixed etiology for the cardiomyopathy were included in non-Chagas group.

All deaths were classified according to specified definitions. The agreement of two members of the study on the cause of death was mandatory. Sudden death was defined as an unexpected death occurred within 1 hour of the onset of new symptoms or occurred unwitnessed in a previously stable patient [8].

Heart failure death was defined as a death that occurred because of worsening or intractable heart failure, which included cardiogenic shock, pulmonary edema and terminal arrhythmias during hospital stay for aggravation heart failure.

Other cardiovascular death was defined as a death that occurred after a cerebrovascular accident, vascular disease, myocardial infarction or cardiovascular procedure. Cerebrovascular accident was defined as a persistent disturbance of neurological function. Diagnosis required characteristic history, physical examination, imaging techniques and/or autopsy data.

Myocardial infarction (MI) death was defined as a death that occurred after a verified acute MI. Noncardiac death was defined as a death resulting from a noncardiac reason. Unknown death was defined as a death that did not have a definitive cause.

Patients were categorized according to the New York Heart Association functional class [9] during evaluation of the medical staff of our heart failure clinic.

### Results
A total of 412 patients were enrolled in the REMADHE trial. For the purpose of the current study, we excluded patients with left ventricular ejection fraction ≥50% (60 patients) and those who had ICD (10 patients) and we censored nine patients at the time of transplantation. All analyses and graphs were performed with SPSS statistical software version 13.0 and Graphpad Prism software version 5.0.

### Ethics Statement
The study protocol was approved by the institutional ethics committee of Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo and all patients provided written informed consent. All data analyzed were anonymized.
patients also had higher proportion of females and larger left ventricular ejection fraction (Table 1).

Chagas patients had a higher incidence of death related to cerebrovascular accident and non-cardiovascular deaths. They also had a higher number of hospitalizations and long-term hospital stay (Table 2).

All-Cause, Heart Failure and Sudden Death Mortality Analysis

Altogether 185 (54.1%) patients died. Death occurred in 31 (56.4%) Chagas patients and 154 (53.7%) non-Chagas patients. Kaplan-Meier cumulative event curves for all-cause, heart failure and sudden death mortality are shown in Figures 2, 3 and 4.

The cumulative incidence of all-cause mortality was higher in patients with Chagas heart disease compared to non-Chagas patients (figure 2). Additionally, the cumulative incidence of heart failure mortality was higher in Chagas patients compared to non-Chagas (figure 3). Nevertheless, when we analyzed the cumulative incidence of sudden death mortality, there was no difference between the two groups (figure 4).

The influence of etiology on heart failure and sudden death mortality was further evaluated by Cox proportional-hazards regression. As we have information about New York Heart Association functional class (NYHA FC) only in 296 patients, we did two different models of Cox proportional-hazards regression; Model 1 without information about NYHA FC and Model 2 including NYHA FC (I/II vs III/IV). Other variables included...
were age, gender, etiology (Chagas vs non-Chagas), use of beta-blocker, use of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, use of spironolactone, body mass index, left ventricular ejection fraction, left ventricular end diastolic diameter (LVEDD), group allocated (disease management program versus control), hemoglobin, serum sodium, creatinine clearance, number of hospitalizations, days of hospitalization and number of admissions to emergency care.

Chagas etiology, LVEDD, creatinine clearance and use of amiodarone were independently associated with heart failure mortality on Model 1 and Model 2 (table 3). On the other hand, LVEDD and use of beta-blocker were independently associated with sudden death mortality on both Models 1 and 2 (table 4).

Concerning the toxic effects of amiodarone, it is important to highlight that none patient died from lung toxicity.

Table 1. Characteristics of the study population.

|                                | Total     | Chagas    | Non-Chagas | p   |
|--------------------------------|-----------|-----------|------------|-----|
| Number of patients (%)         | 342       | 55 (16.1) | 287 (83.9) |     |
| Age, median (IQR), years       | 50 (44–58)| 49 (42–55)| 50 (44–58) | 0.316|
| Male (%)                       | 68.4      | 56.4      | 70.7       | 0.036|
| BMI, median (IQR), kg/m²       | 25.0 (22.3–28.4) | 23.5 (21.3–26.4) | 25.3 (22.5–29.0) | 0.003|
| NYHA class* (%)                |           |           |            |     |
| I/II                           | 60.8      | 56.5      | 61.6       | 0.517|
| III/IV                         | 39.2      | 43.5      | 38.4       | 0.517|
| Disease Management Program Group (%) | 67.7      | 65.5      | 66.9       | 0.835|
| LVEDD, median (IQR), mm        | 70 (63–77)| 67 (63–71)| 70 (64–77) | 0.006|
| Etiology: Ischemic/Idiopathic/Others (%) | 29/27/44 | 29/27/44 | 29/27/44 |     |
| LVEF (%)                       | 32 (26–37)| 34 (28–40)| 31 (25–37) | 0.015|
| Hemoglobin, median (IQR), g/dl  | 14.1 (12.9–15.1) | 13.9 (12.6–14.9) | 14.1 (13.0–15.2) | 0.321|
| CrCl, median (IQR), ml/min/1.73 m² | 71.2 (53.5–93.1) | 64.0 (49.3–86.4) | 72.0 (54.1–93.6) | 0.128|
| Serum sodium, median (IQR), mEq/l | 139 (137–141) | 138 (136–140) | 139 (137–141) | 0.700|
| HF Pharmacotherapy (%)         |           |           |            |     |
| Beta-Blocker                   | 73.0      | 38.2      | 79.8       | <0.001|
| ACEI/ARB                       | 95.5      | 96.4      | 95.4       | 0.749|
| Spironolactone                 | 60.4      | 67.3      | 59.0       | 0.251|
| Warfarin                       | 18.4      | 16.4      | 18.8       | 0.667|
| Amiodarone                     | 9.1       | 12.7      | 8.4        | 0.306|

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CrCl, creatinine clearance; NYHA, New York Heart Association functional class; IQR, interquartile range; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter.

*Information available in 296 patients.
doi:10.1371/journal.pntd.0002176.t001

Table 2. Follow-up comparisons between groups.

|                                | Total     | Chagas    | Non-Chagas | p   |
|--------------------------------|-----------|-----------|------------|-----|
| Death from any cause (%)       | 54.1      | 56.4      | 53.7       | 0.712|
| Sudden death (%)               | 22.5      | 14.5      | 24.0       | 0.122|
| Worsening heart failure death (%) | 22.2      | 27.3      | 21.3       | 0.325|
| Other cardiovascular death (%) | 3.8       | 5.5       | 3.5        | 0.484|
| Stroke (%)                     | 0.9       | 3.6       | 0.3        | 0.017|
| Noncardiovascular death (%)    | 0.9       | 3.6       | 0.3        | 0.017|
| Unknown (%)                    | 4.7       | 5.5       | 4.5        | 0.766|

Abbreviations: IQR, interquartile range.
doi:10.1371/journal.pntd.0002176.t002
Figure 2. Cumulative incidence of all-cause mortality rate in Chagas and non-Chagas patients. 
doi:10.1371/journal.pntd.0002176.g002

Figure 3. Cumulative incidence of heart failure mortality rate in Chagas and non-Chagas patients. 
doi:10.1371/journal.pntd.0002176.g003
Severity of Heart Failure and Mode of Death

The relationship between mode of death and NYHA functional class at randomization was analyzed for each etiology. As mentioned before, information about NYHA functional class was available in 296 (87%) patients.

In patients with Chagas heart disease, the proportion of patients who died of worsening heart failure increased substantially as increased functional class (38% vs 57%). On the other hand, the proportion of patients who died of sudden death decreased with the worsening of functional class (31% vs 15%). Furthermore, 23% of deaths in NYHA class I/II were secondary to other cardiovascular causes (Figure 5).

In non-Chagas group, sudden death was the main cause of death throughout the spectrum of NYHA functional class; 47% in both class I/II and class III/IV (figure 5).

Discussion

To the best of our knowledge, this prospective study is the first one to investigate the causes of death in outpatients with Chagas heart disease associated with severe systolic dysfunction in comparison with non-Chagas patients. A recent study investigated risk estimation for cardiac events in Chagas disease but not analyzed the mode of death [10]. The present study found that patients with heart failure caused by Chagas heart disease had a worse prognosis when compared to others as well that the predominant mode of death in these chagasic patients were progressive heart failure throughout the spectrum of NYHA functional class presentation. In addition, the incidence of death related to cerebrovascular accident and non-cardiovascular deaths was higher in Chagas disease. In the same scenario, the main mode of death in non-Chagas group was sudden death. Moreover, in multivariate analysis Chagas heart disease, left ventricular end diastolic diameter, amiodarone use, serum sodium and creatinine clearance were independent risk factors for death from progressive heart failure.

Our finding is divergent from previous anecdotal reports concerning mode of death in chagasic heart failure patients that indicates sudden death as the main cause of death [4]. Prior studies had included few patients with severe heart failure or patients with higher values of left ventricular ejection fraction. Furthermore data were limited to abstracts or the treatments were outdated [4,11]. Otherwise, other publications in Chagas disease had been selected patients with complex ventricular arrhythmias or patients under secondary prevention for sudden death [12,13]. In the largest study in Chagas heart disease, 62.3% of the patient died of sudden death [14]. However the patients received outdated treatment characterized by low rate of beta-blockers (0.2%–2.4%) and of angiotensin-converting enzyme inhibitor (1.9%–21.9%), and unexplained high rates of amiodarone (33.1%–71.9%), that is not in accordance with guidelines for treatment of chagasic heart failure [15,16]. As additional limitations, it was a retrospective study, the left ventricular function was not reported, only 10.4% of the patients were in NYHA functional class III/IV and the mode of death analysis was partially based on precarious Brazilian death certificate. Our results concerning progressive heart failure death are in concordance with other previous publications that included chagasic patients also under outdated treatment [17,18].

![Cumulative incidence of sudden death mortality rate in Chagas and non-Chagas patients.](doi:10.1371/journal.pntd.0002176.g004)
finding of high incidence of stroke causing death in Chagas disease in comparison with other etiologies confirms previous studies [18,19] despite the unexpected recently reported lack of evidence of pro-thrombotic status among patients with Chagas disease [20]. However, cardiac embolus originating from apical aneurysm and left ventricular thrombosis are a recurrent cause of Chagas stroke [21]. The explanation for high incidence of non-cardiovascular death on Chagas heart disease is unknown. However, in general chagasic patients have lower social and nutritional status and higher incidence of comorbidities, which could predispose them to non-cardiovascular death [22].

Some distinguishing clinical and anatomopathological aspects should be noted in Chagas disease that might influence the mode of death. Biventricular impairment with persistent myocarditis, inflammatory infiltrate edema, conduction-band necrosis and myocytolysis, focal and diffuse areas of myocardial hypertrophy, and fibrosis are found in histology of cardiac tissue [23–26]. Also, chronic low-grade parasite persistence drives tissue damage and the autoimmune component of Chagas cardiomyopathy [27]. Even though this autoimmunity may play a role in development of Chagas heart disease, this was never demonstrated in clinical setting. The role of anti-muscarinic antibodies in the determination of mode of death should be investigated [28]. Concerning the effects of chagasic myocarditis in the mode of death, our findings are in agreement with a recent study, which included 181 patients suspected of viral myocarditis followed for 38 months and did not show prevalence of sudden death as mode of death [29].

One would expect the influence of fibrosis in Chagas heart disease determining sudden death as the main mode of death as in ischemic cardiomyopathy. Although pathological findings in Chagas disease reported a pattern of diffuse interstitial fibrosis [30], magnetic resonance imaging study reported a pattern of fibrosis that can vary a lot from diffuse, heterogeneous, small focal to big transmural scars indistinguishable from myocardial infarction [31]. Ischemic cardiomyopathy displays regional fibrosis and scars which seem to have a mechanistic link with malignant ventricular arrhythmias [32]. The remarkable chagasic biventricular impairment, especially right-sided failure has been appointed as an independent predictor of survival in Chagas heart disease [18]. In fact, the complex Chagas heart disease is characterized by multiple clinical and anatomopathological factors that determine the mode of death, the clinical manifestation and the worst prognosis observed in our study as well as in other publications [33,34].

The medical treatment might have influenced our results. The 38% rate of beta-blockers prescription to our chagasic patients cannot be considered substantial but it was in accordance of guidelines at the period of inclusion of REMADHE, when beta-

### Table 3. Cox proportional hazard analysis of risk factors at baseline for heart failure mortality.

| Variable                  | Univariate Analysis |   | Multivariate Analysis |
|---------------------------|---------------------|---|-----------------------|
|                           | Unadjusted HR (95% CI) |  | Model 1, Adjusted HR (95% CI) |  | Model 2, Adjusted HR (95% CI) |
|                           | ρ                   |   | ρ                     |   | ρ                     |
| Age (years)               | NS                  |   |                       |   |                       |
| Male                      | 1.655 (0.964–2.840) | 0.065 | NS                     |   |                       |
| BMI (kg/m²)              | NS                  |   |                       |   |                       |
| NYHA class [a]            | 1.593 (0.964–2.633) | 0.069 | NA                     |   |                       |
| LVEDD (mm)                | 1.038 (1.013–1.063) | 0.003 | 1.071 (1.042–1.101) | <0.001 | 1.071 (1.039–1.104) | <0.001 |
| LVEF (%)                  | 0.027 (0.001–0.486) | 0.015 | NS                     |   | NS                    |
| Hemoglobin (g/dl)         | NS                  |   |                       |   |                       |
| CrCl (ml/min/1,73 m²)     | 0.991 (0.982–1.000) | 0.038 | 0.986 (0.976–0.997) | 0.009 | 0.973 (0.975–0.995) | 0.006 |
| Serum Sodium (mEq/l)      | 0.991 (0.857–0.985) | 0.019 | NS                     |   | NS                    |
| Etiology [b]              | 2.034 (1.150–3.599) | 0.015 | 2.382 (1.204–4.711) | 0.013 | 2.764 (1.343–5.688) | 0.006 |
| Beta-Blocker [c]          | NS                  |   |                       |   |                       |
| ACEI/ARB [d]              | NS                  |   |                       |   |                       |
| Spironolactone [e]        | NS                  |   |                       |   |                       |
| Amiodarone [f]            | 2.420 (1.304–4.492) | 0.005 | 2.624 (1.326–5.192) | 0.006 | 3.053 (1.469–6.343) | 0.003 |
| Group [g]                 | NS                  |   |                       |   |                       |
| Number of hosp            | NS                  |   |                       |   |                       |
| Days of hosp              | 1.003 (1.001–1.005) | 0.012 | NS                     |   | NS                    |
| Number for EC             | NS                  |   |                       |   |                       |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CrCl, creatinine clearance; EC, emergency care; Hosp, hospitalization; NYHA, New York Heart Association functional class; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; NA: not applicable; NS: not significant;

[a] NYHA class III/VI vs NYHA class I/II; [b] Chagas vs non Chagas; [c] beta-blocker vs no beta-blocker; [d] ACEI/ARB vs no ACEI/ARB; [e] spironolactone vs no spironolactone; [f] amiodarone vs no amiodarone; [g] disease management program vs control; [h] Model 1 not incorporated NYHA functional class and Model 2 included NYHA functional class (information available in 296 patients).

doi:10.1371/journal.pntd.0002176.t003
blockers use was controversial in chagasic patients [35]. Only recently the use of beta-blockers was included in guidelines for the treatment of chagasic patients [15]. However, this 38% rate is considerably higher in comparison with previous studies where the rate of beta-blockers were under 15% [13,14]. In addition, it could partially explain our results given that beta-blockers reduce sudden death in heart failure [36].

Our group has previously published that beta-blockers attenuate the worst prognosis of Chagas heart disease, approaching similar survival to other etiologies [33]. In this study, use of beta-blockers was not independently associated with the risk of death from worsening heart failure but it was independently associated with sudden death mortality. Based on our results, it is reasonable to suppose that beta-blockers reduce sudden death in heart failure [36].

Our group has previously published that beta-blockers attenuate the worst prognosis of Chagas heart disease, approaching similar survival to other etiologies [33]. In this study, use of beta-blockers was not independently associated with the risk of death from worsening heart failure but it was independently associated with sudden death mortality. Based on our results, it is reasonable to suppose that beta-blockers reduce sudden death in heart failure [36].

Specifically regarding the influence of amiodarone, which has been widely prescribed in Chagas heart disease to prevent sudden death and has reached up to 70% rate of use [13,37,38], our cohort had a lower rate of its use (9.1% in total cohort and 12.7% in Chagas group). Despite this, the percentage of sudden death was strikingly lower in this etiology. According to I Latin American Guidelines for the diagnosis and treatment of Chagas’ heart disease, amiodarone is indicated only to (Class I) sustained ventricular tachycardia (symptomatic or not) or symptomatic non-sustained ventricular tachycardia and (Class IIb) for asymptomatic ventricular premature beats or non-sustained ventricular tachycardia [15].

On the other hand, amiodarone was an independent predictor of worsening heart failure death in our cohort, which agrees with previous study in non-chagasic population [39]. This finding could be related to a more strict indication of amiodarone in severe cases. However, this is an issue to be clarified in future studies because amiodarone prescription in our heart failure clinic is indicated according Brazilian Heart Failure Guidelines [16], in clinical situations not necessarily related to worst prognosis in heart failure.

In the face of our findings, an awkward question arises related to the higher incidence of sudden death in populations of chagasic patients despite the high rate of unexplained prescription of amiodarone [13,40]. One issue to be clarified is the potential influence on mortality of amiodarone side effects such as pro-arrhythmic effects, bradycardia and AV block in a disease known to have high incidence of AV block, sick sinus syndrome, besides the increase deaths from circulatory failure and non-cardiovascular death [39,41].

In non-Chagas group, our proportion of sudden death and progressive heart failure death is consistent with literature data. It

Table 4. Cox proportional hazard analysis of risk factors at baseline for sudden death mortality.

| Variable                | Univariate Analysis | Multivariate Analysis |
|-------------------------|---------------------|-----------------------|
|                         | Unadjusted HR (95% CI) | p | Model 1\(^b\), Adjusted HR (95% CI) | p |
| Age (years)             | NS                  |    | 1.038 (1.012–1.064) | 0.003 | 1.038 (1.010–1.065) | 0.005 |
| Male                    | NS                  |    | 1.042 (1.013–1.072) | 0.005 |
| BMI (kg/m\(^2\))        | NS                  |    | 0.068 (0.004–1.259) | 0.071 | NS | NS |
| NYHA class\(^a\)        | NS                  |    | 0.617 (0.384–0.991) | 0.046 | 0.586 (0.361–0.950) | 0.030 |
| LVEDD (mm)              | 1.038 (1.010–1.065) | 0.005 | 1.042 (1.013–1.072) | 0.005 |
| LVEF (%)                | NS                  |    | 0.521 (0.338–0.939) | 0.014 |
| Hemoglobin (g/dl)       | NS                  |    | 1.696 (1.053–2.731) | 0.030 | NS | NS |
| CrCl (ml/min/1.73 m\(^2\)) | NS               |    | 1.710 (1.008–2.899) | 0.047 | NS | NS |
| Serum Sodium (mEq/l)    | NS                  |    | 1.710 (1.008–2.899) | 0.047 | NS | NS |
| LVEF (%)                | NS                  |    | 1.710 (1.008–2.899) | 0.047 | NS | NS |
| Etiology\(^b\)          | NS                  |    | 1.710 (1.008–2.899) | 0.047 | NS | NS |
| Beta-Blocker\(^c\)      | 0.617 (0.384–0.991) | 0.046 | 0.586 (0.361–0.950) | 0.030 | 0.521 (0.338–0.939) | 0.014 |
| ACEI/ARB\(^d\)          | NS                  |    | 1.696 (1.053–2.731) | 0.030 | NS | NS |
| Spironolactone\(^e\)    | NS                  |    | 1.710 (1.008–2.899) | 0.047 | NS | NS |
| Amiodarone\(^f\)        | NS                  |    | 1.710 (1.008–2.899) | 0.047 | NS | NS |
| Group\(^g\)             | 1.710 (1.008–2.899) | 0.047 | 1.710 (1.008–2.899) | 0.047 | NS | NS |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CrCl, creatinine clearance; EC, emergency care; Hosp, hospitalization; NYHA, New York Heart Association functional class; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; NA: not applicable; NS: not significant;

\(^{a}\)NYHA class III/VI vs NYHA class I/II;

\(^{b}\)Chagas vs non Chagas;

\(^{c}\)beta-blocker vs no beta-blocker;

\(^{d}\)ACEI/ARB vs no ACEI/ARB;

\(^{e}\)spironolactone vs no spironolactone;

\(^{f}\)amiodarone vs no amiodarone;

\(^{g}\)disease management program vs control;

\(^{h}\)Model 1 not incorporated NYHA functional class and Model 2 included NYHA functional class (information available in 296 patients).

doi:10.1371/journal.pntd.0002176.t004
is worth noting that our prescription of beta-blockers, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker and spironolactone reflects the state-of-the-art treatment of heart failure. Our results corroborate the EMPHASIS trial, which studied mild non-chagasic heart failure and demonstrated sudden death as main mode of death among cardiovascular death [42]. Also, the CIBIS trial reported sudden death as the predominant mode of death in the bisoprolol arm in non chagasic severe heart failure (NYHA class III/IV) [43].

Limitations
This study contains some limitations that should be acknowledged. First, this study was a single center trial that included patients initially enrolled in another intervention trail. In addition, this was a retrospective analysis though the data were obtained prospectively in REMADHE trial.

Concerning our cohort, Chagas group is considerably smaller than non-Chagas group and Kaplan-Meier curves result may have limited value after 1500 days since the number of Chagas patients at risk is very low. However, it is important to note that the difference in proportion between groups reflects the reality of our population.

In few patients, the mode of death of patients was not clarified. However, it was less than 10%. Unfortunately, the gold standard autopsy studies were not available widespread to confirm certainly the cause of death. Therefore, in most randomized trials as in the REMADHE trial the autopsy is not routinely performed.

Conclusions
Clinicians should keep in mind that in severe Chagas heart disease progressive heart failure plays an important role as the most important mode of death in a scenario of worse prognosis in comparison with other etiologies. The data from this analysis challenges the current understanding of Chagas heart disease and may have implications in the selection of treatment choices considering the mode of death. In addition, our results may influence the development of new strategies for prevention of chagasic heart failure. The amiodarone role in chagasic heart disease should be reevaluated. Moreover, prevention of thromboembolism must be emphatically pursued. Finally, priority should be given to enhance the research related to prevent and treat the progression of heart failure in Chagas disease.

Author Contributions
Conceived and designed the experiments: FB EAB. Performed the experiments: SMAF VSI FDC FB PRC GECS. Analyzed the data: SMAF SM VSI GVG FGMB. Contributed reagents/materials/analysis tools: GVG. Wrote the paper: SMAF SM VSI EAB.
References

1. Bocchi EA, Guimarães G, Tarasouisli F, Spina G, Mangini S, et al. (2009) Cardiomyopathy, adult valve disease and heart failure in South America. Heart 95: 101–109.

2. Committee WE (2002) Control of Chagas disease. World Health Organ Tech Rep Ser 905: i–vi, 1–109, back cover.

3. Gascon J, Bernard C, Pinzao MJ (2010) Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 115: 22–27.

4. Rassi A, Rassi SG (2001) Sudden death in Chagas’ disease. Arq Bras Cardiol 76: 75–96.

5. Bocchi EA, Cruz F, Guimarães G, Pinho Moreira LF, Issa VS, et al. (2008) Long-term prospective, randomized, controlled study using repetitive education at six-month intervals and monitoring for adherence in heart failure outpatients: the REMADHE trial. Circ Heart Fail 1: 115–124.

6. Cruz FD, Issa VS, Ayubi-Ferreira EM, Chazono PR, Souza GE, et al. (2010) Effect of a sequential education and monitoring programme on quality-of-life components in heart failure. Eur J Heart Fail 12: 1009–1015.

7. Bocchi EA, Bellotti G, Mocelin AO, Uip D, Bacal F, et al. (1996) Heart transplantation for chronic Chagas’ heart disease. Ann Thorac Surg 61: 1727–1733.

8. Bocchi EA, Moreira LF, de Moraes AV, Bacal F, Sosa E, et al. (1994) Arrhythmias and sudden death after dynamic cardiomyoplasty. Circulation 90: 1107–1111.

9. (1994) The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis. Boston: Little, Brown.

10. Nunes MC, Reis RC, Colosimo EA, Barbosa FB, et al. (2011) Risk estimation approach in Chagas disease is still needed. Int J Cardiol 147: 294–296.

11. Marè C, Cardoso RH, Barretto AC, de Luz PL, Bellotti G, et al. (1994) Survival and predictors of survival in patients with congestive heart failure due to Chagas’ cardiomyopathy. Circulation 90: 3089–3102.

12. Cardinnall-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC (2007) Predictors of all-cause mortality for patients with chronic Chagas’ heart disease receiving implantable cardioverter-defibrillator therapy. J Cardiovasc Electrophysiol 18: 1236–1240.

13. Sarabanda AV, Marín-Neto JA (2011) Predictors of mortality in patients with Chagas’ cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol 34: 54–62.

14. Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. (2006) Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med 355: 799–808.

15. Andrade JP, Marín Neto JA, Paola AA, Vilas-Boas FS, Oliveira GM, et al. (2011) I Latin American Guidelines for the diagnosis and treatment of chagas’ heart disease: executive summary. Arq Bras Cardiol 96: 434–442.

16. Bocchi EA, Marcondes-Braga FG, Bacal F, Ferraz AS, Albuquerque D, et al. (2012) Avaliação da diretriz brasileira de insuficiência cardíaca crônica. Arq Bras Cardiol 98: 1–73.

17. Bestetti RB, Maciel G (1997) Clinical course of Chagas’ heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 60: 167–193.

18. Nunes MC, Rocha MO, Ribeiro AL, Colosimo EA, Rezende RA, et al. (2008) Right ventricular dysfunction is an independent predictor of survival in patients with dilated chronic Chagas’ cardiomyopathy. Int J Cardiol 127: 372–379.

19. Rassi A, Marín-Neto JA (2010) Chagas disease. Lancet 373: 1388–1402.

20. Melo LM, Souza GE, Valim LR, Moreira LF, Damico EA, et al. (2010) Study of pro-thrombotic and pro-inflammatory factors in Chagas cardiomyopathy. Arq Bras Cardiol 95: 635–642.

21. Carad-Artal FJ (2007) Stroke: a neglected complication of American trypanosomiasis (Chagas’ disease). Trans R Soc Trop Med Hyg 101: 1073–1080.

22. Bricen˜o-Leo´n R (2009) [Chagas disease in the Americas: an ecohealth perspective]. Cad Saúde Pública 25 Suppl 1: S71–S82.

23. Bocchi E, Kallil R, Bacal F, de Lourdes Higuchi M, Meneghetti C, et al. (1998) Magnetic Resonance Imaging in Chronic Chagas’ Disease: Correlation with Endomyocardial Biopsy Findings and Gallium-67 Cardiac Uptake. Echocardiography 15: 279–283.

24. Bocchi EA (2010) Exercise training in Chagas’ cardiomyopathy: trials are welcome for this neglected heart disease. Eur J Heart Fail 12: 782–784.

25. Boghiolo L (1976) [Anatomic causes of heart failure in chronic Chagas cardiopathy (myocarditis) studied comparatively with the anatomic causes of heart failure in other cardiopathies]. II. Arq Bras Cardiol 29: 479–483.

26. Boghiolo L (1976) [Anatomic causes of cardiac insufficiency in chronic chagasic cardiopathy (myocarditis) studied in comparison to anatomic causes of cardiac insufficiency in other cardiopathies]. Part II. Arq Bras Cardiol 29: 419–424.

27. Medei E, Pedroza RS, Benchimol Barbosa PR, Costa GC, Hernández CC, et al. (2007) Human antibodies with muscarinic activity modulate ventricular repolarization: basis for electrical disturbance. Int J Cardiol 115: 373–380.

28. Kindermann I, Kindermann M, Kandolf R, Klingl K, Bültmann B, et al. (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118: 639–648.

29. Rossi MA (1991) The pattern of myocardial fibrosis in chronic Chagas’ heart disease. Int J Cardiol 30: 335–340.

30. Rochitte CE, Oliveira PF, Andrade JM, Ianni BM, Parga JR, et al. (2005) Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol 46: 1553–1558.

31. Iles L, Pluher H, Levkoff L, Butler MJ, Kistler PM, et al. (2011) Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 57: 821–828.

32. Isa VS, Amaral AF, Cruz FD, Ferreira SM, Guimarães GV, et al. (2010) Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail 3: 82–88.

33. Bocchi EA (1994) [Update on indications and results of the surgical treatment of Chagas’ cardiomyopathy using cardiomyoplasty]. Arq Bras Cardiol 63: 523–530.

34. Cardiologia SBd (2002) [Review of the II Guidelines of the Sociedade Brasileira de Cardiologia for the diagnosis and treatment of heart failure]. Arq Bras Cardiol 79 Suppl 4: 1–30.

35. Domanski MJ, Krause-Steinrauf H, Massie BM, Deechowwa P, Follmann D, et al. (2009) Impact of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 55: 821–828.

36. Kimmitt P, Wolpert LM, Bortman GR, Perrone SV, Bortman GR, et al. (1994) Pro-thrombotic and pro-inflammatory factors in Chagas cardiomyopathy. Arq Bras Cardiol 65: 377–387.

37. Doval HC, Nol DR, Grasselli HO, Perrone SV, Bortman GR, et al. (1994) Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344: 493–498.

38. Scanavacca MI, Sosa EA, Lee JH, Bellotti G, Filgogi F (1990) [Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia]. Arq Bras Cardiol 54: 367–371.

39. Torp-Pedersen C, Metra M, Spark P, Lukas MA, Mouller C, et al. (2007) The safety of amiodarone in patients with heart failure. J Card Fail 13: 340–343.

40. Rassi Junior A, Gabriel Rassi A, Gabriell Rassi S, Rassi Junior L, Rassi A (1995) [Ventricular arrhythmia in Chagas disease. Diagnostic, prognostic, and therapeutic features]. Arq Bras Cardiol 65: 377–387.

41. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, et al. (2009) Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 120: 2170–2176.

42. Zairas I, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, et al. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11–21.

43. (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353: 9–13.